

RESEARCH

AMBUJA CEMENTS | TARGET: Rs 375 | -2% | HOLD

Soft realisations weigh on margins

KEC INTERNATIONAL | TARGET: Rs 500 | -3% | HOLD

Standalone margin remains weak

TATA STEEL | TARGET: Rs 140 | +26% | BUY

Project visibility improving, maintain BUY

ORIENT CEMENT | TARGET: Rs 140 | +10% | HOLD

Listless performance

SUMMARY

AMBUJA CEMENTS

- Q4 revenue growth muted at 8% YoY on tepid realisations and limited volumes owing to a labour strike
- EBITDA margin down 160bps YoY despite savings from softer fuel cost and logistics cost control
- We cut FY24/FY25 EPS by 5%/4%, translating to a revised TP of Rs 375 (vs. Rs 387); maintain HOLD as positives priced in

[Click here for the full report.](#)

KEC INTERNATIONAL

- Q4 revenue/PAT ahead of estimates at Rs 55bn/Rs 722mn; revenue growth guidance of 15%+ for FY24 on strong order inflow
- SAE Brazil now EBITDA positive but falling standalone margin a worry; full-year margin guidance at ~7%
- FY24/FY25 EPS estimates upped 4%/1%; TP unchanged at Rs 500 on rollover – maintain HOLD

[Click here for the full report.](#)

Daily macro indicators

Ticker	02-May	03-May	Chg (%)
US 10Y yield (%)	3.42	3.34	(9bps)
India 10Y yield (%)	7.09	7.01	(9bps)
USD/INR	81.89	81.83	0.1
Brent Crude (US\$/bbl)	75.3	72.3	(4.0)
Dow	33,685	33,414	(0.8)
Hang Seng	19,934	19,699	(1.2)
Sensex	61,355	61,193	(0.3)
India FI (US\$ mn)	28-Apr	02-May	Chg (\$ mn)
FI-D	(34.7)	(126.6)	(92.0)
FI-E	791.0	365.9	(425.1)

Source: Bank of Baroda Economics Research



TATA STEEL

- Q4 demonstrated a strong comeback from a low point in India; Europe likely to recover gradually from Q2FY24
- Improving project visibility to drive 10% EBITDA CAGR over FY23-FY26 even at mid-cycle margin assumptions
- Maintain BUY with an unchanged TP of Rs 140 based on 5.75x (blended) FY25E EV/EBITDA

[Click here](#) for the full report.

ORIENT CEMENT

- Focus on realisation gains curbed Q4 volume growth at 5% YoY, indicating lacklustre demand in key areas
- Operating efficiencies lags behind industry, keeping margins under pressure
- Maintain HOLD for a TP of Rs 140 (unchanged), valuing the stock at 5x FY25E EV/EBITDA

[Click here](#) for the full report.

HOLD
 TP: Rs 375 | ▼ 2%

AMBUJA CEMENTS

Cement

04 May 2023

Soft realisations weigh on margins

- Q4 revenue growth muted at 8% YoY on tepid realisations and limited volumes owing to a labour strike
- EBITDA margin down 160bps YoY despite savings from softer fuel cost and logistics cost control
- We cut FY24/FY25 EPS by 5%/4%, translating to a revised TP of Rs 375 (vs. Rs 387); maintain HOLD as positives priced in

Milind Raginwar | Yash Thakur
 research@bobcaps.in

Realisations soft: ACEM reported muted Q4FY23 revenue growth of 8% YoY (+3% QoQ) to Rs 42.6bn primarily owing to weak realisations. Volumes grew 8% YoY (+5% QoQ) to 8.1mn tonnes, while realisations stayed flat YoY (-2% QoQ) at Rs 5,255/t. The impact of a labour strike at the company’s Himachal Pradesh unit was partly countered by clinker shift from Rajasthan to cater North and supported by an increase in blended cement).

Operating cost pressure easing: Operating cost rose 2% YoY to Rs 4,282/t (-6% QoQ) as energy cost (adj to RM cost) grew 13% YoY (-8% QoQ) to Rs 2,350/t, with the clinker factor down from 62.5% to 60.6%. Kiln cost fell 10%, from 2.3/kcal to Rs 2.1/kcal on a better fuel mix and group coal procurement synergies. RM cost rose 51% YoY (+11% QoQ) to Rs 1,073/t due to higher external purchases, logistics cost fell 1% YoY (+6% QoQ) to Rs 1,151/t on better direct dispatches (78% from 64%) and a higher rail mix (30% from 26%). Other expenditure at Rs 4.6bn fell ~15% YoY/ QoQ.

EBITDA margin contracts YoY: EBITDA at Rs 7.9bn was flat YoY (+26% QoQ) due to poor realisations. EBITDA margin shrank 160bps YoY (+335bps QoQ) to 18.5% and EBITDA/t declined 8% YoY (+20% QoQ) to Rs 973/t. PAT was flat YoY (+36% QoQ) at Rs 5bn. Excluding restructuring cost of Rs 0.8bn, PAT grew 18% YoY (+36% QoQ).

Capacity expansion plans: ACEM announced no plans beyond the greenfield capacity additions at Chandrapur (Maharashtra), Bhatpara (W. Bengal) and Mundra (Gujarat), where commissioning is targeted by Q2FY25 – an ambitious schedule, in our view, given that equipment ordering is yet to commence.

Maintain HOLD: ACEM’s operating efficiency drive is a key positive, though capacity building is unlikely to contribute meaningfully before FY25. The stock is currently trading at 13x FY25E EV/EBITDA. We cut our FY24/FY25 EPS estimates by 5%/4% to bake in ACEM’s accounting year change, leading to a revised SOTP-based TP of Rs 375 (vs. Rs 387), set at an unchanged 13x FY25E standalone EV/EBITDA. Our TP implies a replacement cost of Rs 14bn/mt (consolidated capacity) – 2x premium to the industry average. Upsides appear capped at current valuations and hence we retain HOLD.

Key changes

Target	Rating
▼	◀ ▶

Ticker/Price	ACEM IN/Rs 384
Market cap	US\$ 9.3bn
Free float	37%
3M ADV	US\$ 56.9mn
52wk high/low	Rs 598/Rs 315
Promoter/FPI/DII	63%/11%/17%


Source: NSE | Price as of 3 May 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	3,84,062	3,70,071	4,16,513
EBITDA (Rs mn)	51,223	55,789	68,431
Adj. net profit (Rs mn)	29,024	25,404	29,899
Adj. EPS (Rs)	11.7	12.8	15.1
Consensus EPS (Rs)	11.7	15.6	17.9
Adj. ROAE (%)	9.3	7.6	9.0
Adj. P/E (x)	32.8	30.0	25.5
EV/EBITDA (x)	14.2	9.8	7.6
Adj. EPS growth (%)	(20.0)	9.4	17.7

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional | FY23 is for 15 months due to a change in year-end from December to March

Stock performance



Source: NSE



HOLD
 TP: Rs 500 | ▼ 3%

KECI INTERNATIONAL

| Capital Goods

| 04 May 2023

Standalone margin remains weak

- Q4 revenue/PAT ahead of estimates at Rs 55bn/Rs 722mn; revenue growth guidance of 15%+ for FY24 on strong order inflow
- SAE Brazil now EBITDA positive but falling standalone margin a worry; full-year margin guidance at ~7%
- FY24/FY25 EPS estimates upped 4%/1%; TP unchanged at Rs 500 on rollover – maintain HOLD

Vinod Chari | Swati Jhunjunwala
 Nilesh Patil
 research@bobcaps.in


Strong topline: KECI's Q4FY23 topline at Rs 55.3bn (+29% YoY/+26% QoQ) was 14% ahead of our expectations led by strong growth in both the T&D and non-T&D businesses. Order traction continued for the T&D and civil segments. Consolidated EBITDA margin expanded sequentially while the standalone margin fell further. Adj. PAT stood at Rs 722mn (-36% YoY), ahead of our estimate of Rs 578mn. KECI aims to lower interest cost by 50bps in FY24 from 3.1% in FY23.

Standalone margin slips further: The company in Q4 posted its second quarter of sequential margin expansion following steady deterioration in the recent past. Consolidated EBITDA margin at 5.1% rose 60bps QoQ but dipped 80bps YoY. The standalone margin continued to slip further, clocking in at 4.1% (-310bps YoY, -50bps QoQ), as delayed clearances for some legacy orders weighed on profitability. With SAE Brazil turning EBITDA-positive in Q4 and newer order flows at higher rates, management expects a pronounced margin recovery in FY24.

Healthy guidance: Management has guided for revenue growth in excess of 15% for FY24 anchored by strong order inflows of Rs 240bn. EBITDA margin is guided to recover from the trough of H2FY23. Management sees a ~100bps increase in margin by H1FY24, exiting FY24 at ~7%. Net working capital days are expected to improve to ~110 days, closer to KECI's long-term target of <100 days. Order inflow traction is expected to persist on the back of industry tailwinds.

Headwinds yet to abate; maintain HOLD: A burgeoning order book of Rs 300bn+ and structural industry tailwinds bode well for KECI. However, margin recovery, debt and working capital management remain concerns. Additionally, pending recoveries from the Middle East pose a risk. We raise our FY24/FY25 EPS estimates by 4%/1% to bake in the Q4FY23 performance and roll valuations over to Mar'25E, which keeps our TP unchanged at Rs 500. We continue to value the stock at a 14x P/E multiple – a 20% discount to the five-year average – and maintain HOLD.

Key changes



Ticker/Price	KECI IN/Rs 514
Market cap	US\$ 1.6bn
Free float	47%
3M ADV	US\$ 1.9mn
52wk high/low	Rs 526/Rs 346
Promoter/FPI/DII	52%/13%/26%


Source: NSE | Price as of 4 May 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	172,817	202,357	236,340
EBITDA (Rs mn)	8,297	13,747	18,742
Adj. net profit (Rs mn)	1,760	5,647	9,450
Adj. EPS (Rs)	6.8	22.0	36.8
Consensus EPS (Rs)	6.8	25.5	37.7
Adj. ROAE (%)	4.8	14.1	20.4
Adj. P/E (x)	75.1	23.4	14.0
EV/EBITDA (x)	12.6	7.4	5.8
Adj. EPS growth (%)	(53.2)	220.8	67.4

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



BUY
 TP: Rs 140 | ▲ 26%

TATA STEEL

| Metals & Mining

| 04 May 2023

Project visibility improving, maintain BUY

- Q4 demonstrated a strong comeback from a low point in India; Europe likely to recover gradually from Q2FY24
- Improving project visibility to drive 10% EBITDA CAGR over FY23-FY26 even at mid-cycle margin assumptions
- Maintain BUY with an unchanged TP of Rs 140 based on 5.75x (blended) FY25E EV/EBITDA

Kirtan Mehta, CFA
 research@bobcaps.in

Strong Q4 recovery from a low point: TATA's adj. Q4FY23 EBITDA at Rs 72bn was 26% ahead of Bloomberg consensus and 40% ahead of our forecast driven by a beat in the standalone business, which clocked a Rs 16.7k/t EBITDA margin.

Q1 likely to be flat: We expect softer margins in India and limited improvement in Europe for Q1FY24. While a planned maintenance shutdown would weigh on India, natural gas hedges and partial operations in the Netherlands would keep costs high for Europe. High coking coal consumption cost and softer steel prices would impact both.


Improving project visibility ...: At Kalinganagar, TATA commenced production of FHCR coils and pellets, besides guiding for a halt to external pellet buying from Q2FY24, commissioning of the 2.2mtpa CRM complex over the next 12-18 months and start-up of the new 5mtpa BF over 12 months. At the Netherlands, TATA has started relining of BF6 in April with a completion target of H1FY24 and is close to completing the 1.6mt cold mill upgrade. At NINL, it has ramped up the plant to a 1mt annualised run-rate within two quarters of start-up and is now working on stabilising margins. TATA is also targeting board approval for the NINL expansion in FY24.

...to kick-off earnings growth: We currently model for a 10% EBITDA CAGR over FY23-FY26 factoring in conservative ramp-up assumptions for upcoming projects, including 70% utilisation for the 5mtpa TSK expansion and mid-cycle margins.

Hard decision on UK operations could dispel overhang: TATA cautioned that stability issues at the UK upstream plant may force stakeholders to decide a viable replacement option for the plant over the next 12-18 months. Even in the worst case, a restructuring would mean the continuation only of downstream operations, where management believes the impact is likely to be under GBP 1bn.

Maintain BUY: We maintain our SOTP-based TP of Rs 140, assigning the stock an unchanged blended FY25E EV/EBITDA multiple of 5.75x which values Indian operations at 6x and European operations at 4.5x, adding incremental value for the Kalinganagar expansion at Rs 92bn. Given 26% upside potential, we maintain BUY.

Key changes



Ticker/Price	TATA IN/Rs 111
Market cap	US\$ 16.5bn
Free float	66%
3M ADV	US\$ 56.4mn
52wk high/low	Rs 132/Rs 83
Promoter/FPI/DII	34%/21%/21%


Source: NSE | Price as of 4 May 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	2,416	2,181	2,203
EBITDA (Rs mn)	323	338	397
Adj. net profit (Rs mn)	88	123	176
Adj. EPS (Rs)	7.2	10.1	14.4
Consensus EPS (Rs)	7.2	10.7	14.2
Adj. ROAE (%)	8.1	11.5	15.0
Adj. P/E (x)	15.5	11.0	7.7
EV/EBITDA (x)	6.1	5.8	5.1
Adj. EPS growth (%)	(78.4)	41.0	42.5

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



HOLD
 TP: Rs 140 | ▲ 10%

ORIENT CEMENT

| Cement

| 04 May 2023

Listless performance

- Focus on realisation gains curbed Q4 volume growth at 5% YoY, indicating lacklustre demand in key areas
- Operating efficiencies lags behind industry, keeping margins under pressure
- Maintain HOLD for a TP of Rs 140 (unchanged), valuing the stock at 5x FY25E EV/EBITDA

Steady revenue growth, focus on realisation gains: ORCMNT's Q4FY23 revenue grew 9% YoY (+20% QoQ) to Rs 8.7bn. Volume recovery was slow at 5% YoY (+20% QoQ) to 1.7mn tonnes as the company focused on realisation gains (+4% YoY, flat QoQ as prices were 0.5% lower than Q3).

Cost driven by high energy cost, softening QoQ: Operating cost rose 8% YoY (-5% QoQ) to Rs 4,287/t due to higher energy expenses which climbed 22% YoY (+2% QoQ) to Rs 1,620/t (Rs 2,242/t adjusting for raw material cost, +15% YoY, flat QoQ). Logistics cost rose 6% YoY (-1% QoQ) to Rs 1,364/t owing to higher transportation by road during Q4 (84% from 75% in the year-ago quarter) and average distance slightly above 300km. Other expenditure declined 6% YoY (-2% QoQ) to Rs 797mn.

Cost inflation keeps margins under pressure: EBITDA declined 9% YoY (+54% QoQ) to Rs 1.4bn with 315bps YoY margin contraction to 15.9% (+360bps QoQ from a lower base of 12.3%). EBITDA/t was at Rs 812/t vs. Rs 933/t in Q4FY22. Adj. PAT fell 8% YoY (+145% QoQ) to Rs 674mn.

Capacity expansion plans: Chittapur expansion will double capacity from the current 3mt (2mt clinker), with work to commence from Q3FY24. Devapur expansion is guided to be delayed until the grinding unit is under construction as the Tiroda project has been cancelled. The company plans to set up a 2mt grinding unit at Madhya Pradesh, with work to commence by FY26.

Performance triggers weak, retain HOLD: We expect the pace of capacity expansion to slow considerably following the cancellation of Tiroda plans and attendant delays for the linked Devapur clinkerisation. The Chittapur and Madhya Pradesh grinding units are unlikely to fructify before FY26. This would guard the balance sheet from stress but cap growth triggers. Cost inflation is likely to constrain margin gains as well. We thus maintain our HOLD rating for a TP of Rs 140 (unchanged), valuing the stock at 5x FY25E EV/EBITDA, which implies a replacement cost of Rs 40bn/mt – 42% below the industry average.

Milind Raginwar | Yash Thakur
 research@bobcaps.in

Key changes



Ticker/Price	ORCMNT IN/Rs 127
Market cap	US\$ 317.5mn
Free float	62%
3M ADV	US\$ 0.7mn
52wk high/low	Rs 149/Rs 96
Promoter/FPI/DII	38%/6%/11%


Source: NSE | Price as of 4 May 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	29,375	37,917	42,259
EBITDA (Rs mn)	3,738	4,693	6,017
Adj. net profit (Rs mn)	1,228	1,757	2,725
Adj. EPS (Rs)	6.0	8.6	13.3
Consensus EPS (Rs)	6.0	11.7	12.4
Adj. ROAE (%)	7.8	10.5	14.6
Adj. P/E (x)	21.1	14.8	9.5
EV/EBITDA (x)	7.7	5.8	4.3
Adj. EPS growth (%)	(53.4)	43.1	55.1

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

Stock performance



Source: NSE



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (“US”) OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**

Logo:  **BOBCAPS**
 TRUST | INNOVATION | EXCELLENCE

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("**FCA**") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.